4//SEC Filing
GUINAN MARK 4
Accession 0001209191-22-054816
CIK 0001679082other
Filed
Oct 27, 8:00 PM ET
Accepted
Oct 28, 4:41 PM ET
Size
5.8 KB
Accession
0001209191-22-054816
Insider Transaction Report
Form 4
GUINAN MARK
Director
Transactions
- Award
Common Shares
2022-10-26+9,859→ 9,859 total
Footnotes (2)
- [F1]The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person as the annual non-employee director grant. The RSUs shall (x) vest in full on the earlier to occur of (i) October 26, 2023 and (ii) the date that is one day prior to the Issuer's 2023 annual shareholder meeting, subject in each case to the Reporting Person providing continuous service to the Issuer on such date, or (y) to the extent the RSUs have not vested as of the Effective Time, vest pro rata based on the number of days the Reporting Person has served since October 26, 2022 (by using 365 days for a full year), and the vested RSUs shall be entitled to the RSU Consideration as set forth in Section 2.04(b)(i) of the Merger Agreement, and the unvested RSUs shall be forfeited without consideration as of the Effective Time.
- [F2]Each capitalized term not defined above has the meaning assigned to it in that certain Agreement and Plan of Merger by and among the Issuer, Sumitovant Biopharma Ltd., Zeus Sciences Ltd., and, solely with respect to Article IX and Annex A, Sumitomo Pharma Co., Ltd. dated October 23, 2022 (the "Merger Agreement").
Documents
Issuer
Myovant Sciences Ltd.
CIK 0001679082
Entity typeother
Related Parties
1- filerCIK 0001505998
Filing Metadata
- Form type
- 4
- Filed
- Oct 27, 8:00 PM ET
- Accepted
- Oct 28, 4:41 PM ET
- Size
- 5.8 KB